BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22673390)

  • 1. Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation.
    Thaci B; Ulasov IV; Ahmed AU; Ferguson SD; Han Y; Lesniak MS
    Gene Ther; 2013 Mar; 20(3):318-27. PubMed ID: 22673390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
    Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
    Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
    Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
    Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
    Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
    Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
    Lamfers ML; Gianni D; Tung CH; Idema S; Schagen FH; Carette JE; Quax PH; Van Beusechem VW; Vandertop WP; Dirven CM; Chiocca EA; Gerritsen WR
    Cancer Res; 2005 Oct; 65(20):9398-405. PubMed ID: 16230403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy.
    Kim CK; Ahmed AU; Auffinger B; Ulasov IV; Tobias AL; Moon KS; Lesniak MS
    Mol Ther; 2013 Nov; 21(11):2063-73. PubMed ID: 23883863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MT1-MMP silencing by an shRNA-armed glioma-targeted conditionally replicative adenovirus (CRAd) improves its anti-glioma efficacy in vitro and in vivo.
    Ulasov I; Borovjagin AV; Kaverina N; Schroeder B; Shah N; Lin B; Baryshnikov A; Cobbs C
    Cancer Lett; 2015 Sep; 365(2):240-50. PubMed ID: 26052095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.
    Zhu ZB; Makhija SK; Lu B; Wang M; Rivera AA; Kim-Park S; Ulasov IV; Zhou F; Alvarez RD; Siegal GP; Curiel DT
    Int J Oncol; 2005 Jul; 27(1):237-46. PubMed ID: 15942665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.
    Ahmed AU; Thaci B; Alexiades NG; Han Y; Qian S; Liu F; Balyasnikova IV; Ulasov IY; Aboody KS; Lesniak MS
    Mol Ther; 2011 Sep; 19(9):1714-26. PubMed ID: 21629227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
    Zhang W; Fulci G; Buhrman JS; Stemmer-Rachamimov AO; Chen JW; Wojtkiewicz GR; Weissleder R; Rabkin SD; Martuza RL
    Mol Ther; 2012 Jan; 20(1):37-45. PubMed ID: 21915104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
    Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
    Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
    Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
    Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy.
    Ulasov IV; Shah N; Kaverina NV; Lee H; Lin B; Lieber A; Kadagidze ZG; Yoon JG; Schroeder B; Hothi P; Ghosh D; Baryshnikov AY; Cobbs CS
    Oncotarget; 2015 Feb; 6(6):3977-87. PubMed ID: 25738357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
    Harada A; Uchino J; Harada T; Nakagaki N; Hisasue J; Fujita M; Takayama K
    Cancer Sci; 2017 Jan; 108(1):116-123. PubMed ID: 27783867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
    Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
    Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy.
    Nandi S; Ulasov IV; Rolle CE; Han Y; Lesniak MS
    J Gene Med; 2009 Nov; 11(11):1005-11. PubMed ID: 19688792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
    Ulasov IV; Sonabend AM; Nandi S; Khramtsov A; Han Y; Lesniak MS
    Br J Cancer; 2009 Apr; 100(7):1154-64. PubMed ID: 19277041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
    Kaliberova LN; Krendelchtchikova V; Harmon DK; Stockard CR; Petersen AS; Markert JM; Gillespie GY; Grizzle WE; Buchsbaum DJ; Kaliberov SA
    Cancer Gene Ther; 2009 Oct; 16(10):794-805. PubMed ID: 19363468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
    Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
    Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.